Workflow
Oral Polyclonal Antibodies
icon
搜索文档
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
Newsfile· 2025-10-17 23:07
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price TargetOctober 17, 2025 11:07 AM EDT | Source: Emerging Growth ResearchNew York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-month price target of $4.00, representing over 80% upside from the Company's recent closing price of $2.20.The initiation repo ...